Global $14.9 Bn Nucleic Acid Based Gene Therapy Markets, 2015-2020, 2025F, 2030F
April 07, 2022 04:58 ET
|
Research and Markets
Dublin, April 07, 2022 (GLOBE NEWSWIRE) -- The "Nucleic Acid Based Gene Therapy Global Market Opportunities And Strategies To 2030, By Nucleic Acid Technology, Application, End User" report has been...
Global Gene Editing Beyond CRISPR Market (2022 to 2035) - Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies
March 22, 2022 06:13 ET
|
Research and Markets
Dublin, March 22, 2022 (GLOBE NEWSWIRE) -- The "Gene Editing beyond CRISPR Market: Focus on Zinc Finger Nucleases, Transcription Activator-Like Effector Nucleases and Meganucleases Edited Therapies:...
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
March 09, 2022 16:01 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative...
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
February 28, 2022 16:01 ET
|
Intellia Therapeutics, Inc.
Achieved 86% and 93% mean serum TTR reduction by day 28 at 0.7 mg/kg and 1.0 mg/kg doses, respectively, with dose-dependent reductions observed across all four dose levelsDurable serum TTR reductions...
Global CRISPR Market & Competition Landscape 2021-2028 Featuring Profiles of Integrated DNA Technologies, Intellia Therapeutics, Horizon Discovery Group, and Precision Biosciences Among Others
February 04, 2022 05:38 ET
|
Research and Markets
Dublin, Feb. 04, 2022 (GLOBE NEWSWIRE) -- The "Global CRISPR Market 2021-2028" report has been added to ResearchAndMarkets.com's offering. The global CRISPR market is anticipated to display growth...
Outlook on the Oligonucleotide Synthesis Global Market - Featuring Abbott Diagnostics, Amyris and Bayer Among Others
February 03, 2022 04:38 ET
|
Research and Markets
Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Oligonucleotide Synthesis Markets - Forecasts by Oligo Length, Application, and Product - With Executive and Consultant Guides and including Customized...
Genome Editing Market Size ($16.98Bn by 2028) Lead by CRISPR Technology (18.4% CAGR) - Exclusive Research Report by The Insight Partners
January 20, 2022 12:48 ET
|
The Insight Partners
New York, Jan. 20, 2022 (GLOBE NEWSWIRE) -- According to our new research study on “Genome Editing Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Technology (CRISPR, TALEN,...
Global CRISPR Gene Editing Market Report 2021-2031: Opportunities in Expanding Gene and Cell Therapy Area & CRISPR Gene Editing Scope in Agriculture
January 14, 2022 05:33 ET
|
Research and Markets
Dublin, Jan. 14, 2022 (GLOBE NEWSWIRE) -- The "CRISPR Gene Editing Market - A Global and Regional Analysis: Focus on Product, Application, End User, and Country-Wise Analysis - Analysis and...
$11.7 Bn Genome Editing/Genome Engineering Markets - Global Analysis & Forecasts to 2026
December 20, 2021 05:28 ET
|
Research and Markets
Dublin, Dec. 20, 2021 (GLOBE NEWSWIRE) -- The "Genome Editing/Genome Engineering Market - Global Forecast to 2026" report has been added to ResearchAndMarkets.com's offering. The global genome...
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
December 13, 2021 07:30 ET
|
Intellia Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using...